NASDAQ:GRFS - GRIFOLS S A/S Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$19.36 +0.12 (+0.62 %)
(As of 01/21/2019 04:00 PM ET)
Previous Close$19.24
Today's Range$19.17 - $19.55
52-Week Range$17.42 - $25.18
Volume1.12 million shs
Average Volume750,583 shs
Market Capitalization$13.31 billion
P/E Ratio17.60
Dividend Yield1.80%
Beta1.05
Grifols, S.A., a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, such as intravenous immune globulin, Factor VIII, alpha-1 proteinase inhibitor, and albumin; and intramuscular immunoglobulins, antithrombin III, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products comprising analytical instruments, reagents, software, and related products for use in clinical and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment offers products used by hospitals, as well as parenteral solutions and enteral nutritional fluids. The Bio Supplies segment provides biological products for non-therapeutic uses. The Others segment renders manufacturing services to third party companies. The company also provides infusion solutions, nutrition products, and medical devices for use in hospitals and clinics; and engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

Receive GRFS News and Ratings via Email

Sign-up to receive the latest news and ratings for GRFS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GRFS
CUSIPN/A
Phone34-93-571-2200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$4.88 billion
Cash Flow$1.4394 per share
Book Value$5.97 per share

Profitability

Net Income$749.04 million

Miscellaneous

Employees18,296
Market Cap$13.31 billion
OptionableOptionable

GRIFOLS S A/S (NASDAQ:GRFS) Frequently Asked Questions

What is GRIFOLS S A/S's stock symbol?

GRIFOLS S A/S trades on the NASDAQ under the ticker symbol "GRFS."

How often does GRIFOLS S A/S pay dividends? What is the dividend yield for GRIFOLS S A/S?

GRIFOLS S A/S declared a special dividend on Thursday, November 8th. Stockholders of record on Monday, December 3rd will be given a dividend of $0.2283 per share on Tuesday, December 11th. This represents a dividend yield of 2.25%. The ex-dividend date is Friday, November 30th. This is a positive change from GRIFOLS S A/S's previous special dividend of $0.01. View GRIFOLS S A/S's Dividend History.

When did GRIFOLS S A/S's stock split? How did GRIFOLS S A/S's stock split work?

GRIFOLS S A/S's stock split on the morning of Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly created shares were issued to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of GRIFOLS S A/S stock prior to the split would have 200 shares after the split.

When is GRIFOLS S A/S's next earnings date?

GRIFOLS S A/S is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for GRIFOLS S A/S.

What price target have analysts set for GRFS?

7 brokerages have issued 12-month price objectives for GRIFOLS S A/S's stock. Their forecasts range from $19.00 to $19.00. On average, they expect GRIFOLS S A/S's stock price to reach $19.00 in the next twelve months. This suggests that the stock has a possible downside of 1.9%. View Analyst Price Targets for GRIFOLS S A/S.

What is the consensus analysts' recommendation for GRIFOLS S A/S?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GRIFOLS S A/S in the last year. There are currently 2 sell ratings, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for GRIFOLS S A/S.

Has GRIFOLS S A/S been receiving favorable news coverage?

Press coverage about GRFS stock has been trending very positive this week, InfoTrie reports. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. GRIFOLS S A/S earned a coverage optimism score of 3.2 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

Who are some of GRIFOLS S A/S's key competitors?

Who are GRIFOLS S A/S's key executives?

GRIFOLS S A/S's management team includes the folowing people:
  • Mr. Raimon Grifols Roura, Co-Chief Exec. Officer & Exec. Director (Age 55)
  • Mr. Tomás Dagá Gelabert, Vice Sec. & External Director (Age 63)
  • Mr. Víctor Grifols Deu, Co-CEO & Exec. Director (Age 42)
  • Mr. Alfredo Arroyo Guerra, CFO & Corp. VP (Age 61)
  • Mrs. Eva Bastida Tubau, Corp. VP and Director of Scientific & Medical Affairs

Who are GRIFOLS S A/S's major shareholders?

GRIFOLS S A/S's stock is owned by many different of retail and institutional investors. Top institutional investors include Cardinal Capital Management (0.00%), Moody National Bank Trust Division (0.00%) and Quadrant Capital Group LLC (0.00%).

Which institutional investors are buying GRIFOLS S A/S stock?

GRFS stock was bought by a variety of institutional investors in the last quarter, including Quadrant Capital Group LLC, Cardinal Capital Management and Moody National Bank Trust Division.

How do I buy shares of GRIFOLS S A/S?

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GRIFOLS S A/S's stock price today?

One share of GRFS stock can currently be purchased for approximately $19.36.

How big of a company is GRIFOLS S A/S?

GRIFOLS S A/S has a market capitalization of $13.31 billion and generates $4.88 billion in revenue each year. The biotechnology company earns $749.04 million in net income (profit) each year or $1.10 on an earnings per share basis. GRIFOLS S A/S employs 18,296 workers across the globe.

What is GRIFOLS S A/S's official website?

The official website for GRIFOLS S A/S is http://www.grifols.com.

How can I contact GRIFOLS S A/S?

GRIFOLS S A/S's mailing address is AVINGUDA DE LA GENERALITAT 152-158 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at 34-93-571-2200 or via email at [email protected]


MarketBeat Community Rating for GRIFOLS S A/S (NASDAQ GRFS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  285 (Vote Underperform)
Total Votes:  510
MarketBeat's community ratings are surveys of what our community members think about GRIFOLS S A/S and other stocks. Vote "Outperform" if you believe GRFS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GRFS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/21/2019 by MarketBeat.com Staff

Featured Article: What is the yield curve?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel